Affinity Capital Management

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

ValenTx is a development-stage medical device company that focuses on minimally-invasive methods for the treatment of morbid obesity. The company was founded in 2002 and headquartered in Maple Grove, Minnesota.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

myocor is a medical company that develops and distributes a range of therapeutic products to its clients. The company develops and provides evaluations on technologies to treat mitral regurgitation and heart failure. Furthermore, the technologies assist in the improvement of cardiac function. myocor was founded in 1996 and is based in Minnesota.

Disc Dynamics is a healthcare company. They design and develop medical products. The Company offers surgical alternatives for the treatment of lower back problems and disc diseases. It offers DASCOR Disc arthroplasty system, a catheter-based minimally invasive nucleus replacement technology for the treatment of degenerated lumbar discs. Disc Dynamics was founded by Jeffrey Felt in 2000 and is headquartered in Eden Prairie, Minnesota.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.